Cellectricon announces world`s first system for high throughput RNAi screening

"We are pleased to collaborate with EPFL and look forward to bringing this state-of-the-art system to the market," says Dr. Mattias Karlsson, CEO at Cellectricon. "Cellaxess-HT will be the first of its kind on the market and will significantly impact drug discovery by opening the door to using more biologically relevant cell types in genome wide RNAi screening."

"We are impressed by the unprecedented high throughput delivery of genetic materials the Cellaxess-HT system offers. We believe that Cellaxess-HT has the potential to greatly advance our efforts in our RNAi research programs," says Dr. Gerardo Turcatti, Director of the Biomolecular Screening Facility at EPFL, Lausanne, Switzerland.